Advertisement

Topics

Enanta’s EDP-938 Achieved its Primary and Secondary Endpoints in Phase 2a Human Challenge Study in Healthy Adults with Respiratory Syncytial Virus

10:17 EDT 14 Jun 2019 | Speciality Pharma Journal

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results that demonstrated that EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo in its Phase 2a human …

Original Article: Enanta’s EDP-938 Achieved its Primary and Secondary Endpoints in Phase 2a Human Challenge Study in Healthy Adults with Respiratory Syncytial Virus

NEXT ARTICLE

More From BioPortfolio on "Enanta’s EDP-938 Achieved its Primary and Secondary Endpoints in Phase 2a Human Challenge Study in Healthy Adults with Respiratory Syncytial Virus"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...